AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience

[1]  M. Korbonits,et al.  AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation , 2017, Endocrine connections.

[2]  P. Chanson,et al.  Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. , 2015, Endocrine-related cancer.

[3]  S. Ellard,et al.  Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers , 2015, The Journal of clinical endocrinology and metabolism.

[4]  F. Keleştimur,et al.  Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant? , 2015, Pituitary.

[5]  Julian R. E. Davis,et al.  Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort , 2014, The Journal of clinical endocrinology and metabolism.

[6]  J. Lupski,et al.  Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. , 2014, The New England journal of medicine.

[7]  M. Korbonits,et al.  Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. , 2014, European journal of endocrinology.

[8]  J. Honegger,et al.  Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. , 2014, The Journal of clinical endocrinology and metabolism.

[9]  P. Chanson,et al.  Founder Effect in Recurring AIP Mutation Causing Familial Isolated Pituitary Adenoma Syndrome , 2014 .

[10]  M. Korbonits,et al.  Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. , 2014, The Journal of clinical endocrinology and metabolism.

[11]  P. Chanson,et al.  Acromegaly and McCune-Albright syndrome. , 2014, The Journal of clinical endocrinology and metabolism.

[12]  B. Xing,et al.  Screening for AIP gene mutations in a Han Chinese pituitary adenoma cohort followed by LOH analysis. , 2013, European journal of endocrinology.

[13]  A. Tabarin,et al.  Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. , 2013, European journal of endocrinology.

[14]  L. Aaltonen,et al.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. , 2013, Endocrine reviews.

[15]  N. Pellegata,et al.  Multiple endocrine neoplasia type 4. , 2013, Frontiers of hormone research.

[16]  M. Korbonits,et al.  Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal α-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition , 2012, PloS one.

[17]  P. Chanson,et al.  Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. , 2012, The Journal of clinical endocrinology and metabolism.

[18]  A. Tabarin,et al.  High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. , 2011, European journal of endocrinology.

[19]  M. Korbonits,et al.  AIP and its interacting partners. , 2011, The Journal of endocrinology.

[20]  M. Dattania,et al.  Characterization of aryl hydrocarbon receptor-interacting protein ( AIP ) mutations in familial isolated pituitary adenoma families , 2011 .

[21]  M. Korbonits,et al.  AIP mutation in pituitary adenomas , 2011 .

[22]  M. Turgut,et al.  Comparison of three methods for the estimation of the pituitary gland volume using magnetic resonance imaging: a stereological study , 2011, Pituitary.

[23]  R. Paschke,et al.  Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. , 2010, The Journal of clinical endocrinology and metabolism.

[24]  A. Paetau,et al.  Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. , 2010, The American journal of pathology.

[25]  G. Arnaldi,et al.  Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. , 2010, European journal of endocrinology.

[26]  C. Stratakis,et al.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways , 2010, Expert review of endocrinology & metabolism.

[27]  E. Menis,et al.  The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect? , 2010, Journal of endocrinological investigation.

[28]  R. Paschke,et al.  Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. , 2010, The Journal of clinical endocrinology and metabolism.

[29]  Markus Mäkinen,et al.  The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. , 2009, The American journal of pathology.

[30]  S. Melmed.  Acromegaly pathogenesis and treatment. , 2009, The Journal of clinical investigation.

[31]  Shuichi Matsumura,et al.  Genetic Discontinuity Between Local Hunter-Gatherers and Central Europe’s First Farmers , 2009, Science.

[32]  M. Tanner,et al.  Kyphoplasty for patients with multiple myeloma is a safe surgical procedure: results from a large patient cohort. , 2009, Clinical lymphoma & myeloma.

[33]  Jan Lubinski,et al.  Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas , 2008, Clinical endocrinology.

[34]  Julian R. E. Davis,et al.  The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[35]  C. Stratakis,et al.  Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune–Albright syndrome, familial acromegaly and genetic defects in sporadic tumors , 2008, Reviews in Endocrine and Metabolic Disorders.

[36]  Youngsook Lee,et al.  Deletion of the Aryl Hydrocarbon Receptor-associated Protein 9 Leads to Cardiac Malformation and Embryonic Lethality* , 2007, Journal of Biological Chemistry.

[37]  Jan Lubinski,et al.  Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations , 2007, Proceedings of the National Academy of Sciences.

[38]  R. Paschke,et al.  Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene , 2006, Science.

[39]  S. Melmed.  Pathogenesis of pituitary tumors. , 1999, Endocrinology and metabolism clinics of North America.

[40]  T. Kirkwood,et al.  An International Collaborative Study of Factor VIII , 1977, Thrombosis and Haemostasis.